Obstetric use of the antimalarial drug mefloquine has historically been discouraged during the first trimester and immediately before conception owing to concerns of potential fetal harm. With the rise of resistance to the antimalarial drug sulfadoxine-pyrimethamine (SP), mefloquine is now being considered as a replacement for SP for universal antenatal administration to women from malaria-endemic regions.
INTRODUCTION
Mefloquine is a highly lipophilic, 4-quinolinemethanol antimalarial that is structurally related to quinine. First developed nearly 40 years ago by the U.S. military in response to concerns over rising chloroquine resistance [1] , its high efficacy and convenient weekly dosing schedule led to its rapid adoption for first-line use as chemoprophylaxis among U.S. military forces [2] [3] [4] . Recently, the widespread use of mefloquine within the U.S. military has been discontinued in favor of doxycycline [5] , the predominant chemoprophylaxis in use before mefloquine's U.S. licensure in 1989 [3] .
Previously considered to be the drug of choice among civilians for prophylaxis against chloroquine-resistant malaria [6] [7] [8] [9] [10] and highly prescribed to travelers [11] , mefloquine's high rate of neuropsychiatric side effects [12] [13] [14] [15] [16] [17] , particularly among women [18] [19] [20] , and high prevalence of contraindications [21, 22] to its safe use have led to its gradual replacement by alternative medications. The drug has lost market share in Australia [23] [24] [25] , the United Kingdom [26, 27] , and the United States [28] . The innovator product (Lariam; F. Hoffman-La Roche Ltd.) was recently withdrawn without explanation from the U.S. market, although generic formulations remain widely available [29] .
Use of Mefloquine in Pregnancy
Despite loss of popularity among travelers [28] , recent recommendations [30] [31] [32] have suggested a potential niche use for mefloquine among pregnant women for whom more popular antimalarials remain contraindicated [32] . Although early epidemiological evidence clearly linked mefloquine to an increased risk of miscarriage [33, 34] and stillbirth [35, 36] and original prescribing guidance and package inserts labeled the drug as pregnancy category C [37] , the U.S. Food and Drug Administration (FDA) recently approved a change in the drug's pregnancy rating to B. On the basis of this change, the U.S. Centers for Disease Control and Prevention now recommend mefloquine at all stages of pregnancy for women who cannot otherwise avoid travel to areas of chloroquine-resistant malaria where prophylaxis is indicated [38] in place of doxycycline and primaquine, which remain contraindicated [32] , and atovaquone-proguanil, for which inadequate safety studies during pregnancy are available [32, 39] .
Among women from malaria-endemic areas, risk-benefit decisions for the use of mefloquine during pregnancy are informed by considerations of the deleterious effects of placental malaria on fetal outcomes, including a risk of intrauterine growth retardation and low birth weight [40] . As a result, mefloquine had historically been widely used in the developing world despite existing cautions. Soon after its European licensure in the mid-1980s, the drug was widely distributed among pregnant women along the northwestern Thai border [36] and in rural Malawi [40] , where it was administered both in treatment of diagnosed malaria [36] and in presumptive treatment and chemoprophylaxis, predominantly during the second and third trimesters [35, 41] . Amid reports of an increased risk of stillbirth [35, 36] and declining efficacy, widespread use of antenatal mefloquine was ultimately abandoned [36, 42] , and the original recommendations of the drug manufacturer to avoid mefloquine during pregnancy were reinforced [36] . As practices throughout malaria-endemic regions have evolved to encourage widespread antenatal administration of treatment doses of antimalarials regardless of the presence of disease, in a practice known as Intermittent Presumptive (or, alternatively, Preventive) Treatment (IPT) [43, 44] , the use of mefloquine has been replaced in full by use of the better-tolerated [45] drug combination sulfadoxinepyramethamine (SP) [46, 47] . Use of SP remains the standard of care in IPT [48] , but with the spread of malaria strains resistant to SP after more than a decade of use across the developing world, and with alternative antimalarial drugs [32, 39] , including the newer artemisinin-based combination treatments (ACT), not recommended for use in the first trimester [49] , mefloquine is once again being considered for widespread administration as IPT to asymptomatic pregnant women [43] [44] [45] .
The recent interest in recommending mefloquine for obstetric use contrasts with cautions enforced over 20 years of licensure in the developed world, during which time very little new experimental evidence has emerged to inform alternative recommendations. As recently as 2010, the World Health Organization conceded there remains ''very limited information on the safety and efficacy of most antimalarials in pregnancy, particularly during the first trimester'' [50] .
Mefloquine Gap Junction Blockade
Independent of its antimalarial activity, mefloquine is a potent blocker of human gap junction intercellular communication (GJIC) [51] , and this property has been widely exploited by the neurobiology and neurophysiology research communities to evaluate the important role of GJIC in normal functioning of the central nervous system [3] . Growing appreciation of the similarly important role of GJIC in developmental biology [52, 53] has led to concerns that mefloquine gap junction (GJ) blockade may affect embryologic implantation or placental development in women exposed to the drug [54] . Unlike other common antimalarials, mefloquine remains concentrated in tissues for months after dosing [55] , creating the possibility of unintended exposure long after use and, thus, of the drug having a potentially veiled effect on fertility or pregnancy outcomes.
The lack of significant direct evidence for the safety of mefloquine calls for a critical evaluation of available indirect evidence to guide the drug's rational use during the periconceptional period. Here, the role of GJIC in early pregnancy is reviewed, and the pharmacokinetics and pharmacodynamics of mefloquine are explored, with a particular focus on the drug's potential effects on embryonic implantation and placental development. The epidemiology and postmarketing surveillance of mefloquine in relation to pregnancy loss also are reviewed, and possible directions for future research are explored.
ROLE OF GJs IN PREGNANCY
In early human pregnancy, successful implantation of a fertilized embryo depends upon modulation of the receptive female endometrium, a process that occurs in a complex series of steps mediated by maternal and embryonic intercellular signaling during trophoblast invasion [56, 57] . GJIC plays a critical role in effecting intercellular signaling in the development and differentiation of endometrial decidual tissue and placental trophoblast during this process [58, 59] . Impairment of GJIC during early development is therefore a plausible mechanism by which mefloquine GJ blockade may affect pregnancy outcome.
The GJs between cells are formed by the apposition of connexon hemichannels, each composed of hexameric, radially arranged transmembrane proteins commonly known as connexins [57] . When formed, GJs facilitate the passage of ions and low-molecular-weight products directly between adjacent cells, thus linking them metabolically and electrically [57] . A variety of connexin proteins are expressed in human tissues, including GJ protein alpha 1 (GJA1), commonly known as connexin 43 for its molecular weight in kilodaltons, which forms the GJA1=connexin 43s that predominate in decidua and trophoblast [57, 60] .
In endometrium, GJA1 shows increased expression during the estrogen-dominated proestrous and estrous phases and is suppressed in the progesterone-dominated metestrous and diestrous phases [57] . In rat models, following conception, endometrial expression of GJA1 is briefly suppressed by progesterone signaling during preimplantation [60] but may be induced by isolated 17b-estradiol application [61] . Embryonic implantation triggers an increase in endometrial GJA1 expression [60] , coincident with estradiol-mediated differentiation of endometrium and angiogenesis during decidualization [52, 62] .
Effects of Impaired GJIC
Recently, it has been found that women with recurrent early pregnancy loss have significantly reduced expression of GJA1 in their decidua and placental chorionic villi [58] . In women with miscarriage, decidual cells obtained from curettage form significantly fewer GJs as compared to those from women with electively terminated but otherwise normal pregnancies [52] . Genetic knockdown of GJA1 within the endometrial stroma similarly results in arrest of embryonic growth and pregnancy loss [62] , confirming an essential role for endometrial GJA1 in early gestation.
Similarly, GJA1 facilitates GJIC associated with the fusion process of cytotrophoblastic cells leading to the formation and subsequent maintenance of the syncytiotrophoblast [63] [64] [65] . In human embryos, GJA1 is widely expressed in the developing blastocyst [66] , and although mutations in GJA1 are not universally lethal [67] , experimental truncation of the GJA1 cytoplasmic tail adversely affects cell fusion in the developing human trophoblast [59] .
Taken together, these results suggest that impaired GJA1 GJIC within the differentiating embryonic trophoblast may be associated with abnormal placentation and that reduced GJA1 GJIC in the differentiating decidua may be associated with a risk of early pregnancy loss.
Effects of Pharmacologic GJ Blockade
It has been proposed that drugs causing blockade of endometrial or trophoblast GJA1 GJs may result in a similarly increased risk of pregnancy loss [53, 54] . Experimental support for this hypothesis has recently been obtained via the nonspecific GJ blockers 18a-glycyrrhetinic acid (18a-GA) [53] , octanol [53] , and carbenoxolone [59] . 18a-GA halfmaximally blocks nonspecific GJs at concentrations of 1.5 lM, octanol blocks nonspecific GJs at concentrations of 0.5-1.0 mM, and carbenoxolone half-maximally blocks nonspecific GJs at concentrations of 3 lM [68] .
Exposing human endometrial tissue specimens obtained from healthy, reproductive-age volunteers to noncytotoxic concentrations of 18a-GA at 50 lM or octanol at 1.5 mM NEVIN prevented subsequent hormonally directed morphological differentiation and angiogenesis within endometrial stromal cell cultures and significantly increased markers of inflammation, producing conditions less favorable to successful implantation [53] . These results were similar to those obtained by confirmatory transgenic modification of GJIC by targeted knockout of GJA1 with short hairpin ribonucleic acid [53] . Similarly, exposing human trophoblast tissue to noncytotoxic concentrations of carbenoxolone at 125 lM completely blocked trophoblast fusion, a result similar to that obtained through genetic modification of GJA1 expression [59] .
Taken together, these results provide compelling support for a causal association of pharmacologic inhibition of GJA1 GJIC in the decidua and developing trophoblast with a risk of subsequent pregnancy loss.
EXPERIMENTAL EVIDENCE
Both mefloquine and its parent compound quinine produce a dose-dependent blockade of GJs and result in impaired GJIC in vitro, as determined by measuring junctional currents in a transfected human neuroblastoma cell model [51] . No studies confirming this effect have yet been performed in decidua or trophoblast. At concentrations of 30 lM in the transfected cell model, however, mefloquine effectively blocks GJA1 GJIC, whereas it displays virtually no effect at 3 lM and nearly a half-maximal effect at 10lM [51] . The mechanism of mefloquine GJ blockade is thought to be more specific and dose-dependent than that of 18a-GA, octanol, and carbenoxolone across distinct members of the connexin class [68] .
Adverse pharmacologic effects of GJ blockers have been demonstrated in vitro, but for mefloquine to plausibly affect GJA1 GJIC in the decidua and trophoblast and, therefore, have a deleterious effect on embryonic implantation and early placental development in vivo, it would need to accumulate at concentrations of 10-30 lM, far higher than those typically found within serum.
No studies have directly measured mefloquine tissue concentrations in vivo in the decidua, trophoblast, or placenta from human volunteers receiving mefloquine, but inference can be drawn from a considerable body of pharmacokinetic evidence in both human and animal studies. Mefloquine is highly lipophilic and accumulates preferentially in cell lipid bilayers, where in the absence of active efflux, evidence suggests it may accumulate at relevant concentrations after treatment or chemoprophylactic dosing.
Mefloquine Pharmacokinetics
The current U.S. FDA-approved package insert reports steady-state concentrations of mefloquine of approximately 2.6-5.2 lM are achieved after long-term chemoprophylactic dosing [69] . Other studies have reported lower [70] [71] [72] and wider-ranging [71, 73] concentrations. This variability is partially explained by differential bioavailability across available formulations [29, 74, 75] , though relatively wide concentration ranges suggest significant population heterogeneity in serum pharmacokinetics. The factors underlying this heterogeneity provide insights regarding the drug's unusual tissue pharmacokinetics and, thus, the likelihood of accumulation in the decidua and trophoblast.
After oral dosing, no more than 1%-2% of the total drug contained in oral formulations is ultimately found within the circulation. In separate studies, 1000 mg (2.6 mmol) of oral drug resulted in peak serum levels of approximately 1000 ng/ ml (2.6 lM) [55, 76] . Assuming a whole-blood volume of approximately 5 L and a maximum whole-blood concentration twofold over that of serum, the estimated total mefloquine in circulation totals only 26 lmol, or 1% of the administered total. In another study, 250 mg (0.66 mmol) of oral drug resulted in peak serum levels of approximately 570 ng/ml (1.5 lM) [77] , yielding an estimated total mefloquine in circulation of 15 lmol, or slightly more than 2% of the administered total.
Although frequently described as being highly protein bound [78] , mefloquine is far more strongly attracted to membrane phospholipids [79] , binding weakly to hemoglobin and other proteins in comparison [80] . Despite high binding affinity for red blood cell (RBC) membranes [80] , concentrations in studies of whole blood are only modestly higher than concentrations in serum [78, 81, 82] , consistent with the relatively small total RBC membrane volume. Rather than serving as a significant depot for the drug, RBCs appear to mediate the drug's distribution, rapidly transferring it from the circulation to concentrate in higher-affinity peripheral tissue [78, 81] , consistent with mefloquine's high but notably heterogeneous volume of distribution, calculated at between 5 L/kg [77] and 50 L/kg [55] across populations.
Pharmacokinetics in Women and in Pregnancy
Despite significant variability, the volume of distribution for mefloquine exhibits a linear trend with body mass [83] , perhaps explaining why women tend to have higher serum levels than men after equivalent dosing [72, [84] [85] [86] . Yet women also exhibit significantly greater variability in serum levels between doses [84] and appear to have a lower and narrower volume of distribution, even after adjusting for body mass [84, 85] . The reasons for this are unclear, but they may relate to the lower lean body mass of women as compared to men. Counterintuitively, mefloquine may accumulate at slightly higher concentrations in muscle than in adipose tissue [78] , affording a relatively lower volume in which the drug may distribute in women.
Pregnancy does not increase the clearance or metabolism of mefloquine [87] , but in late pregnancy, its volume of distribution tends to rise significantly [88] , contributing to reduced serum concentrations. In one study of nine pregnant and eight nonpregnant women, average peak mefloquine concentrations were lower among pregnant patients, and the total apparent volume of distribution was larger and exhibited greater variation, consistent with both an expanded circulating blood volume and an increased, and possibly more heterogeneous, tissue binding [87] . These results suggest that the fetus and placenta may serve as locations of additional heterogeneous mefloquine accumulation.
Placental Pharmacokinetics
Findings in vitro support pharmacokinetic evidence of significant distribution into the placental circulation. In a study of six human term placentas obtained after single vaginal deliveries [89] placed into a closed system and perfused with plasma containing mefloquine initially at a typical chemoprophylactic concentration of 800 ng/ml (2.1 lM), rapid distribution into placental tissue was observed. Average maternal circuit serum concentration dropped to 231 ng/ml (0.6 lM), whereas placental tissue concentration rose to 2909 ng/ml (7.6 lM) on a g/ml basis [90] at 3 h [89] , a greater than 10-fold accumulation. In this model, the maternal circuit was infused with an initial mefloquine dose of only 240 lg, less than 1:1000 that contained in a single 250-mg tablet. Had the maternal circuit better simulated in vivo conditions and been maintained near 2 lM, it is tempting to speculate that placental MEFLOQUINE AND RISK OF PREGNANCY LOSS tissue concentrations would have exceeded a 10-fold accumulation over these serum levels, to 20 lM or greater. Such observations would be consistent with the at least 10-fold accumulation observed in other organs, including lung [2] , kidney [2, 78] , and liver [2, 78] , and with the known tendency of lipophilic molecules to readily diffuse across barrier membranes and accumulate in placenta [91] .
Active Efflux of Mefloquine
Although the lipophilicity of mefloquine, its tendency to passively diffuse across membranes, and its placental accumulation in vitro provide evidence that the drug may concentrate in the decidua and trophoblast relative to serum, these observations do not consider the potential effects of active efflux in vivo, particularly during early pregnancy, which may serve to moderate this effect. In living systems, active efflux in the blood-placental barrier is thought to control the accumulation of and protect the developing embryo from various maternal xenobiotics [92, 93] .
A primary mechanism of active efflux in the blood-placental barrier is the inducible ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, a membrane-spanning protein previously known as permeability glycoprotein, or P-gp [94] . ABCB1 is heterogeneously expressed in endometrium [95] [96] [97] . In a study of gestational endometrium, patterns of uterine expression were correlated with rising serum and tissue progesterone, and expression of ABCB1 was extensive and localized apically, suggesting a role for ABCB1 in uteroplacental transport of signaling molecules during implantation [98] . Apical ABCB1 expression in trophoblast is also widespread and highest during early development and at the time of decidual differentiation [92, 99, 100] , then decreases throughout pregnancy [101] [102] [103] . In first-trimester placenta, ABCB1 expression localized by immunohistochemistry was demonstrated primarily at the syncytiotrophoblast border [103, 104] , with efflux primarily apical and directed toward the maternal circulation [104] . Expression was also localized in the syncytiotrophoblast in preterm placenta [103] and the syncytiotrophoblast microvillous membrane of term placentas [105] . Taken together, these findings suggest a protective role for ABCB1 against mefloquine accumulation during early placentation that remains throughout gestation.
Although the current U.S. package insert for mefloquine states that the clinical relevance of mefloquine being an ABCB1 substrate is unknown [69] , ABCB1 exhibits significant genetic heterogeneity [106] [107] [108] and is subject to drug-induced variation [94, 105, 109, 110] in expression and function. Although studies in decidua are limited, studies in term placentas [106] [107] [108] suggest a plausible multifactorial heterogeneity in ABCB1 activity likely to have significant effects on the distribution and accumulation of mefloquine.
Mefloquine Accumulation
For mefloquine to have a deleterious effect on decidual differentiation or trophoblast cell fusion in vivo, it would need to accumulate at concentrations of 10-30 lM to interfere with GJA1 GJIC. Given the heterogeneous serum and tissue pharmacokinetics of the drug, it is reasonable to speculate that moderate and transient accumulation above serum levels may result in such inhibitory concentrations being achieved. With 10-fold or greater lipophilic accumulation of mefloquine into organ tissue observed with loss of active efflux at autopsy [2] , it seems plausible that even modest changes in efflux function could significantly affect tissue concentration.
For example, the tendency toward higher mean serum levels in women may result in serum concentrations exceeding 5 lM [84] . Coupled with a mere twofold accumulation into decidua or trophoblast, tissue mefloquine concentrations could exceed 10 lM. It therefore seems biologically plausible that a subset of the population will experience a combination of elevated serum concentrations and genetic or drug-induced modifications in ABCB1 expression and efflux function that under certain circumstances yield effective tissue mefloquine concentrations of 10-30 lM capable of adversely affecting the viability of the implanting embryo.
EPIDEMIOLOGICAL EVIDENCE
Although retrospective epidemiological investigation of early pregnancy is notoriously challenging, particularly when considering the frequent possibility of unrecognized conception [111] , a limited number of studies support arguments of biological plausibility by providing evidence that mefloquine, in contrast to other agents, is associated with a modestly increased risk of early pregnancy loss and a risk of stillbirth possibly associated with placental anomalies.
Mefloquine and Risk of Spontaneous Abortion
An early study reporting on data from two cohorts of antimalarial users found evidence of an increased risk of spontaneous abortion with mefloquine as compared to nonquinoline antimalarials [33] . The first, a retrospective traveler cohort, included 19 users of SP reporting exposure beginning up to 4 wk before conception and 99 users of mefloquine reporting exposure beginning up to 12 wk before conception, which represent appropriate intervals given the respective serum half-lives of each drug [33] . Among the SP group, spontaneous abortion was not reported, whereas among the mefloquine group, nine spontaneous abortions (9.1%) were reported. The second, a pharmaceutical database cohort, included 153 women prospectively reporting first-trimester exposure to SP and 331 women reporting first-trimester exposure to mefloquine. Among the SP group, four spontaneous abortions (2.6%) were reported, whereas among the mefloquine group, 30 spontaneous abortions (9.1%) were reported (P ¼ 0.01) [33] .
Similarly, an unexpectedly high rate of spontaneous abortion was observed in a cohort of 72 pregnant U.S. Army servicewomen exposed to mefloquine between 1992 and 1994 at the time of conception [34] . Of 36 nonterminated pregnancies for which outcomes were known, 12 (33.3%) ended in spontaneous abortion [34] . This study is particularly strong because of the presumed universal availability of early pregnancy testing and the close follow-up among this cohort.
Mefloquine and Risk of Stillbirth
A retrospective study including 2401 pregnancies not ending in abortion identified at antenatal clinics serving refugees along the western border of Thailand between 1991 and 1994, including 200 women who were exposed to mefloquine during early pregnancy or in the 3 mo before conception, found a statistically higher rate of stillbirth of 4.5% in the mefloquine-exposed group, compared to a rate of 1.8% among 2201 neither receiving antimalarial medication nor diagnosed with malaria (P ¼ 0.02) [36] . Although not statistically significant, three of the nine mefloquine-associated stillbirths were attributed to placenta previa or abruptio. In comparison, among the 21 stillbirths for which records were verifiable among those neither receiving antimalarial medica-NEVIN tion nor diagnosed with malaria, only four were attributed to these causes [36] .
Postmarketing Surveillance
Recent product inserts have recommended that women use contraception for 3 mo upon discontinuation of mefloquine [69] . Given widespread perceptions of risk of fetal harm arising from mefloquine and a consequently high rate of induced abortion associated with its use [33, 34] , it seems plausible that despite recent recommendations that mefloquine may be safely used during the first trimester [31] , most women will nonetheless have attempted to follow package insert guidance to avoid pregnancy following exposure.
An industry-sponsored study that included data through 1996 reported only 1627 worldwide reports of prenatal exposure to mefloquine during the approximately 10-yr surveillance period since initial European licensure [112] , received from among more than 12 million users who were administered the drug [113] [114] [115] . The majority of reports were submitted by health care providers, and only 39 reports were submitted by patients themselves. Of 1526 cases prospectively reported, 246 were induced abortions, and in 363 cases, pregnancy outcome was unknown. Of the remaining 917 cases, only 79 spontaneous abortions and 8 stillbirths were reported [112] .
Such reporting very likely represents only a small fraction of pregnancies, and only limited conclusions can be drawn from such evidence. For example, in 1993, Roche received only slightly more than 200 pregnancy reports from among slightly more than 1.5 million prophylactic users, a reporting rate of approximately 13 per 100 000 users [112] . Yet during this same period, aggressive case finding by the U.S. Army identified 73 pregnancies [34] among a predominantly male force of approximately 25 000 [116] to 30 000 [117] personnel deployed to Somalia, among whom an estimated 93% received mefloquine [118] . This corresponds to a reporting rate of approximately 262 to 314 per 100 000, or at least 20-fold higher than that observed among civilian users during a comparable period.
A recent follow-up study that included 14 additional years of data through 2010 added only 879 additional worldwide reports of prenatal exposure [119] . Of 466 additional prospective exposures with known outcomes, only 33 additional spontaneous abortions were reported, or fewer than three additional spontaneous abortions per year [119] . These very low numbers suggest that routine postmarketing surveillance is considerably affected by reporting bias. Compliance with product insert guidance and limited reporting have thus served to significantly reduce the validity and utility of postmarketing surveillance in evaluating the risk of pregnancy loss associated with mefloquine [120] . Results from these and other epidemiological studies of pregnancy loss among women with periconceptional mefloquine exposure are summarized in Table 1 .
DIRECTIONS FOR FUTURE RESEARCH
Given the methodological challenges inherent in performing both new epidemiological studies and the ethical issues involved in performing human in vivo experiments involving mefloquine, future research efforts may be best directed toward in vivo experiments using appropriate animal models that assess the extent of mefloquine's accumulation in placenta and decidua and its resulting effects on implantation and pregnancy outcome.
Additional experiments in vitro in cultured endometrial stromal cells and trophoblast that attempt to replicate earlier studies of pharmacologic blockade using physiologically plausible concentrations of mefloquine may also prove useful [53, 59] . Such studies may be aided by the availability of viable cell lines for in vitro studies [121] . While establishing that aberrant decidualization might be deleterious in the context of gestation, such studies may also permit further exploration of the intriguing possibility that mefloquine and other GJ blockers may have potential therapeutic efficacy in certain pathologic conditions, including adenocarcinoma and endometriosis [56] .
CONCLUSIONS
Significant controversy and disagreement have accompanied the use of mefloquine in healthy females during early pregnancy [122] , and recent recommendations in favor of such use have been made mostly without direct evidence of safety and after possible misinterpretation of limited epidemiological evidence [31, 32, 38] . Insights regarding the biology of early gestation provide substantial indirect evidence of a deleterious effect for mefloquine in implantation and early placental development and support epidemiological evidence of risk of pregnancy loss. 
MEFLOQUINE AND RISK OF PREGNANCY LOSS
Interestingly, quinine, which shares with mefloquine the ability to block GJA1 GJIC [51] , has long been employed as a folk remedy for self-induced abortion [123, 124] . Although available biological evidence does not support a claim of quinine's efficacy for this purpose beyond the early first trimester, during which it, like mefloquine, may plausibly affect embryonic implantation and early placental development, it is tempting to speculate that anecdotal awareness of reduced fertility associated with exposure may have contributed to its mostly unsuccessful use to attempt abortion of laterterm pregnancies [123] . Unfortunately, frequent reports of using quinine for this purpose have been associated with a significant risk of harm to the mother and fetus [123, [125] [126] [127] .
Given the recent interest in obstetric use of mefloquine and the potential for renewed, widespread administration both in the developed and developing worlds, additional experimental investigation is clearly warranted. While these studies are pending, the evidence presented in this review support a call for renewed adherence, where feasible, to existing mefloquine package insert guidance that women avoid the drug during the periconceptional period.
Reassuringly, a number of prevention strategies are available to minimize periconceptional mefloquine exposure (Table 2 ). For women in the developed world whose travel plans may be flexible, it may be reasonable to recommend deferral of travel until the second trimester, when traveling is generally considered to be safer [39] . For immunologically naïve women traveling to areas with chloroquine-sensitive malaria, chloroquine is generally considered to be safe during the first trimester [39] . For women who must travel to areas with chloroquine-resistant malaria during the periconceptional period, the evidence provided in the present review points to the need for thorough patient education so that a fully informed decision may be made that balances the risks and benefits of available prophylactic antimalarial medications, including mefloquine, against the potential risks of malaria to the mother and developing fetus. In limited cases, practicing mosquitoavoidance measures alone [39, 50] may be an appropriate recommendation. Similarly, for many semi-immune women in malaria-endemic areas of the developing world for whom IPT may be recommended, intermittent screening and treatment [46] may prove to be a practical and safe alternative to IPT. However, because both treatment and chemoprophylaxis of malaria are likely to remain occasionally unavoidable during the periconceptional period, the evidence presented in this review reinforces the need for the development of efficacious antimalarial drugs with proven safety during the first trimester. [46]
ACT IST Under consideration for antenatal administration should SP resistance develop.
[46]
Developed world: immunologically naïve women traveling to malaria-endemic areas Delay of travel to second trimester Recommended as generally safer than travel during the first trimester.
[39] Chloroquine prophylaxis Generally considered safe for use during the first trimester for travel to areas of chloroquine-sensitive malaria.
[39]
Mosquito-avoidance measures May be appropriate under certain conditions. [39, 50] a SP, sulfadoxine-pyrimethamine; IPT, intermittent presumptive/preventive treatment; IST, intermittent screening and treatment; ACT, artemisinin-based combination treatment.
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